Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.35 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.32 |
| ▸ | KMO | O15229 | 2/20 | 0.32 |
| ▸ | GLS | O94925 | 3/20 | 0.32 |
| ▸ | RARG | P13631 | 2/20 | 0.31 |
| ▸ | RARB | P10826 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1784509 | 1.00 | HCAR2 (0.38) | HCAR2DAOALDH1A1GPR35BCL2L1 | |
| SCHEMBL1782124 | 0.93 | GPR35 (0.37) | HCAR2DAOALDH1A1GPR35BCL2L1 | |
| SCHEMBL1783320 | 0.93 | GPR35 (0.37) | HCAR2DAOALDH1A1GPR35BCL2L1 | |
| SCHEMBL1784916 | 0.93 | GPR35 (0.37) | HCAR2DAOALDH1A1GPR35BCL2L1 | |
| SCHEMBL1422730 | 0.86 | GPR35 (0.39) | HCAR2DAOALDH1A1GPR35BCL2L1 | |
| SCHEMBL1422758 | 0.86 | GPR35 (0.39) | DAOALDH1A1GPR35BCL2L1KDM4E | |
| SCHEMBL13363462 | 0.78 | RARG (0.35) | GPR35MAPTRARGRARB | |
| SCHEMBL1422495 | 0.78 | MAP3K14 (0.39) | — | |
| SCHEMBL14878260 | 0.73 | DAO (0.38) | HCAR2DAOALDH1A1GPR35BCL2L1 | |
| SCHEMBL17058612 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2297105-B1 | SUBSTITUTED AMIDES, METHOD OF MAKING, AND USE AS BTK INHIBITORS | GILEAD CONNECTICUT INC (US) | 2015-09-02 | — | — | EP | disclosed |
| US-8426424-B2 | Certain substituted amides, method of making, and method of use thereof | CGI PHARMACEUTICALS, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426424-B2 | Certain substituted amides, method of making, and method of use thereof | CGI PHARMACEUTICALS, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426424-B2 | Certain substituted amides, method of making, and method of use thereof | CGI PHARMACEUTICALS, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-20110118233-A1 | Certain Substituted Amides, Method of Making, and Method of Use Thereof | CGI PHARMACEUTICALS, INC. | 2011-05-19 | — | — | US | disclosed |
| US-20110118233-A1 | Certain Substituted Amides, Method of Making, and Method of Use Thereof | CGI PHARMACEUTICALS, INC. | 2011-05-19 | — | — | US | disclosed |
| US-20110118233-A1 | Certain Substituted Amides, Method of Making, and Method of Use Thereof | CGI PHARMACEUTICALS, INC. | 2011-05-19 | — | — | US | disclosed |
| WO-2009137596-A1 | SUBSTITUTED AMIDES, METHOD OF MAKING, AND USE AS BTK INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118233-A1 | Certain Substituted Amides, Method of Making, and Method of Use Thereof | BTK, SYK, MYD88 | HCAR2 2363/4885DAO 1474/4885ALDH1A1 3393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.